Paul Michael Armistead MD PhD
Hematologic Oncology
Associate Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine
Join to View Full Profile
101 Manning DrChapel Hill, NC 27599
Phone+1 919-966-4131
Dr. Armistead is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Stem cell transplant and cellular therapy
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2005 - 2008
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
University of North Carolina at Chapel Hill School of MedicineClass of 2002
Certifications & Licensure
NC State Medical License 2008 - 2026
TX State Medical License 2005 - 2010
MA State Medical License 2004 - 2005
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification WebCIS, UNC Health Care, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients Start of enrollment: 2018 Mar 01
Publications & Presentations
PubMed
- A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing.Tyler C Dunlap, Jing Zhu, Daniel L Weiner, Ryan M Kemper, Susanna C DeVane
Clinical Pharmacokinetics. 2025-11-01 - Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.Felicia Cao, Yueling Xiu, Michael Mohnasky, Jonathan S Serody, Paul Armistead
Open Forum Infectious Diseases. 2025-09-01 - The Prevalence of Multidrug Resistance in Enterobacterales Is Higher in Patients Undergoing Hematopoietic Stem Cell Transplantation.Tessa M Andermann, Dylan Brown, Thomas Holowka, Luther A Bartelt, Jonathan S Serody
Open Forum Infectious Diseases. 2025-01-01
Press Mentions
Press Ganey Recognizes UNC Health in 2024 Human Experience AwardsJanuary 29th, 2025- North Carolina 6-Year-Old Searching for Bone Marrow DonorDecember 11th, 2024
- Could Baking Soda Fight Leukemia Relapse After Stem Cell Transplant?January 5th, 2021
Grant Support
- MICROFABRICATED INSTRUMENTATION TO MEASURE SPHINGOLIPID SIGNALING IN HUMAN ACUTE MYELOID LEUKEMIAUNIVERSITY OF WASHINGTON2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
